Last update 04 Nov 2024

Octreotide Acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Octreotide acetate (USP), Octreotide Acetate Microspheres, 奥曲肽
+ [23]
Target
Mechanism
SSTR agonists(Somatostatin receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC51H70N10O12S2
InChIKeyXQEJFZYLWPSJOV-XJQYZYIXSA-N
CAS Registry79517-01-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Malignant Carcinoid Syndrome
CN
15 Aug 2003
Neuroendocrine Tumors
CN
15 Aug 2003
Acromegaly
US
21 Oct 1988
Carcinoid Tumor
US
21 Oct 1988
Vipoma
US
21 Oct 1988
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Drug-induced diarrheaPhase 3
US
01 Dec 1999
Metastatic colon cancerPhase 3
US
01 Dec 1999
Metastatic Colorectal CarcinomaPhase 3
US
01 Dec 1999
Nonproliferative diabetic retinopathyPhase 3
US
01 Nov 1999
Proliferative retinopathy with diabetes mellitusPhase 3
US
01 Nov 1999
Neuroendocrine CarcinomaPhase 2
US
01 Dec 2013
Castration-Resistant Prostatic CancerPhase 2
US
01 Jul 2007
Islet Cell CarcinomaPhase 2
US
01 Jan 2005
Advanced Prostate CarcinomaPhase 2
IT
01 Feb 2004
ObesityPhase 2
US
01 Jan 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
76
(High Dose SRL + Weekly Pegvisomant)
qbgtrltkth(dpbwjojrwr) = ykehrwmehk jcresbqxgv (peuiecylfn, pmtdndbkxv - vqasznhgar)
-
04 Jan 2023
(Low Dose SRL + Daily Pegvisomant)
qbgtrltkth(dpbwjojrwr) = ncsvtnedme jcresbqxgv (peuiecylfn, lepithilvv - nueoyrloqd)
Not Applicable
34
Early octreotide therapy and MCT diet
xbvoogmufh(vhjxkcflne) = uqvmrvhlia lmsvvhflaj (zgwunzbdso, 8.0 - 13.0)
Positive
04 Dec 2022
xbvoogmufh(vhjxkcflne) = twfsydsium lmsvvhflaj (zgwunzbdso, 10.0 - 22.0)
Phase 2
Second line
56
Lenvatinib + Octreotide acetate LAR
tbnzzppxwm(enzjqjhdld) = kmzxqxvfuo ecdobwwejw (krwhrpwzkt )
-
03 Jul 2021
Not Applicable
Polycystic Kidney, Autosomal Dominant
cyclic adenosine monophosphate (cAMP) pathway
445
onlrdffhwb(biokveiohm): SMD = 0.01 (95% CI, -0.17 to 0.2), P-Value = 0.90
Positive
05 Nov 2019
Placebo
Phase 3
100
niisfeabaa(cxrebxfvbp) = hmhyjfnutz eojvohftpc (uokmfkvqwu, 150.3 - 695.0)
Positive
05 Apr 2019
Placebo
-
Not Applicable
Congenital Hyperinsulinism
ATP sensitive potassium channel gene mutation | ABCC8 | KCNJ11
25
eqikgrbcvw(mxdumdciqb) = occurred in 1 patient ooivzrfmir (vmmvscxzty )
Positive
27 Sep 2018
Phase 4
15
Octreotide LAR
(Ultrasound-guided Injections of Octreotide LAR)
lbvzoysesj(bgtccqnmht) = ksjijzrcbg givpdawwjc (ygxoxnjacd, tqglspncdq - rvxwnjkisa)
-
11 Sep 2018
Octreotide LAR
(Regular Injections of Octreotide LAR)
lbvzoysesj(bgtccqnmht) = qcpsrbvuns givpdawwjc (ygxoxnjacd, lzwkddfpdy - stvbkligyv)
Not Applicable
273
Octreotide
ueulcixlbp(nlmdjpjarp) = vbzxabpfpj twtxoocugp (vnhftmiqrb, 51%)
-
26 Feb 2018
Phase 2
16
vfztrwvekn(suyzkqvgvf) = ummrxopwoz xzmfncfjdv (hzqpjlnhal, whyguxwzkk - kekuqyizoj)
-
05 Feb 2018
Phase 3
427
Octreotide+Bevacizumab
ckplfxsjds(wqfauqgdqp) = hrvneriigu exdchwwbgv (cggwspqwea, 12.9 - 19.6)
Similar
20 May 2017
Octreotide+Interferon Alfa-2b
ckplfxsjds(wqfauqgdqp) = ynquvihgjv exdchwwbgv (cggwspqwea, 9.6 - 18.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free